BioCentury
ARTICLE | Emerging Company Profile

Killer expansion

How CytoSen is using nanoparticles to expand NK cells

June 8, 2017 12:53 AM UTC

CytoSen Therapeutics Inc.'s nanoparticle technology expands and activates patient-derived NK cells ex vivo with fewer safety risks and manufacturing challenges than other expansion protocols.

Unlike T cells, which mount highly specific immune responses to pathogens or cancer cells, NK cells are components of the innate immune system that recognize and destroy any abnormal cell. That gives them potential against any type of cancer, in contrast to T cells, which have yet to show results beyond hematological malignancies. ...

BCIQ Company Profiles

CytoSen Therapeutics Inc.